These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24650773)

  • 1. Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
    Bassand JP
    EuroIntervention; 2014 Mar; 9(11):1333-41. PubMed ID: 24650773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].
    Fernández D; Penela D; Heras M
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():41-5. PubMed ID: 23498072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
    Harenberg J; Wehling M
    Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antithrombotics for secondary prevention of acute coronary syndrome.
    Goto S; Tomita A
    Clin Cardiol; 2014 Mar; 37(3):178-87. PubMed ID: 24452610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Kar S; Bhatt DL
    Coron Artery Dis; 2012 Sep; 23(6):380-90. PubMed ID: 22728913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anticoagulant therapy in secondary prevention of coronary events].
    Bultas J
    Vnitr Lek; 2014 Dec; 60(12):1023-32. PubMed ID: 25692828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
    Morales-Vidal S; Schneck MJ; Flaster M; Biller J
    Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.